3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech

Vanguard’s healthcare ETF (VHT, $16.6B) is up 5.6% for the month ending July 10 and is near its 52-week high, supported by favorable biotech/weight-loss drug catalysts (Goldman raised 2030 obesity-drug sales forecasts by 15%; Zepbound maker Eli Lilly is a 14% holding). The Vanguard Value ETF (VTV, $179B) is up 14.8% YTD and charges just 0.03%, while the Vanguard Small-Cap ETF (VB, $78.7B) is up 15.4% YTD on improving forward earnings and relatively attractive valuations. Overall message: broadening market breadth beyond tech is benefiting multiple Vanguard style/sector ETFs, though it’s more momentum/risk appetite than a discrete macro or earnings shock.

Analysis

This looks more like a factor-flow regime than a clean fundamental re-rating: if breadth continues to widen, the market is implicitly paying for lower duration and better earnings visibility, which is a headwind for the most crowded mega-cap growth names and a tailwind for cheaper cyclicals and defensives. The near-term winner is likely the basket of stocks that benefit from multiple compression ending rather than heroic revenue assumptions; that favors value-heavy financials/industrials and selective healthcare over long-duration software.

Healthcare is the cleanest defensive expression here, but the real edge is concentrated in a few large names, so the ETF can work even if breadth inside the sector is mediocre. Small caps are the highest-beta beneficiary of any easing in real rates and credit spreads, but they are also the first to give back gains if financing conditions tighten; that makes the move more tactical over 1-3 months than structural unless earnings revisions keep improving.

The contrarian risk is that this is a late-cycle "everything goes up" trade rather than a durable rotation. If 10Y yields back up, spreads widen, or forward EPS revisions roll over, small caps and value should underperform quickly; if GLP-1 pricing or reimbursement headlines turn negative, healthcare breadth will narrow and the rally could become much more top-heavy. The consensus may also be underestimating how much of the value ETF’s upside is actually coming from cyclical tech like MU rather than classic cheap sectors, which makes stock selection more important than style labels.

Key Decisions for Investors

• Long VB / short QQQ for 1-3 months on any pullback in the pair: target 4-6% relative outperformance if breadth keeps widening; cut if QQQ reasserts leadership and the ratio breaks to new lows.
• Long VTV versus SPY over the next quarter as a broader breadth hedge: favor it if financials and industrials keep outperforming; invalidate if rate cuts get pushed out and large-cap growth regains market share.
• Add LLY on weakness or via a 6-12 month call spread rather than chasing the ETF basket: the secular obesity optionality is real, but the valuation makes outright upside more fragile if reimbursement or launch dynamics slow.
• Consider MU / short NVDA as a tactical relative-value pair for 1-3 months: it benefits from a shift from duration to earnings leverage, but stop out if AI capex or memory pricing accelerates enough to re-favor NVDA.
• Watch IWM relative to HYG and the 10Y real yield: if real yields rise or credit spreads widen, reduce small-cap exposure immediately because that is the fastest way this rotation can reverse.